Systemic lupus erythematosus (lupus) is a chronic (long-lasting) autoimmune disease that can affect many parts of the body.

Diagnosis of Systemic Lupus Erythematosus (Lupus) Lupus can be difficult to diagnose because it has many symptoms that come and go and can mimic symptoms of other disorders or diseases.

What is systemic lupus erythematosus (lupus)? Systemic lupus erythematosus (lupus) is a chronic (long-lasting) autoimmune disease that can affect many parts of the body, including the:

Learn about lupus, including how it is diagnosed and treated, and the steps you can take to help you live with the condition.

How is systemic lupus erythematosus (lupus) treated? The goals of treatment for lupus are to: Manage symptoms. ...

Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. People with SLE are often treated with cyclophosphamide (CYC). But CYC can damage a woman s ovaries; it may cause infertility. A drug called GnRHa is sometimes given to protect the ovaries during CYC therapy.

2025年3月10日 · The AMP RA/SLE program used a molecular- and cellular-level approach (“disease deconstruction”) to uncover the biological pathways that play a role in RA and/or SLE. AMP RA/SLE investigators conducted more than 100 synovial (joint) biopsies in RA and more than 200 renal biopsies in SLE.

2025年3月10日 · Both AMP AIM and AMP RA/SLE are components of the Accelerating Medicines Partnership (AMP) which was created in 2014 as a collaborative effort between the NIH, the U.S. Food and Drug Administration, multiple biopharmaceutical and life science companies, nonprofit, and other organizations to transform the current model for developing new ...

2025年3月7日 · The AMP RA/SLE Program brings together the NIH and medical community to address rheumatoid arthritis and lupus with diagnostic and drug advancements. This public-private partnership seeks to develop new ways of identifying and validating promising biological targets for diagnostics and drug development.

2021年11月23日 · Researchers led by a team at NIH have identified a potential treatment to reduce the risk of cardiovascular disease in people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The researchers examined the effects of tofacitinib, an anti-inflammatory drug, on 30 people diagnosed with SLE, which is often referred to as lupus.